Redaction Log

CVR Management (OR), LLC - CVR Acquisition LLC - CVR Acquisition Parent, LLC

Date **11/13/2026**

Redaction #	Document Title	Bates Stamp Range	Reasons for Redaction	Statutory Basis	Partially or Entirely Redacted?
1	Appendix to HCMO-5 Form	HCMO-SELL-0039 to HCMO-SELL-0042	The parties request confidential treatment of certain information provided in the HCMO-5 Form. This information has not been made publicly available in any other forum. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in the parties' operating model. and includes contact information for individuals. The Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a "material change transaction". As such, the parties are requesting further confidential treatment of these	ORS 192.345(23); ORS 415.501(13)(c)	Partially
2	Party A - HCMO-1 Workbook	HCMO-SELL-0029 to HCMO-SELL-0033	Party A requests confidential treatment of certain information provided in the HCMO-1 Workbook. This information has not been made publicly available in any other forum. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in the party's operating model. The Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a "material change transaction". As such, Party A is requesting further confidential treatment of these materials.	ORS 192.345(23); ORS 415.501(13)(c)	Partially
3	Party B - HCMO-1 Workbook	HCMO-BUY-005 to HCMO-BUY-011	Party B requests confidential treatment of certain information provided in the HCMO-1 Workbook. This information has not been made publicly available in any other forum. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in the party's operating model. The Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a "material change transaction". As such, Party B is requesting further confidential treatment of these materials.	ORS 192.345(23); ORS 415.501(13)(c)	Partially
4	Party C - HCMO-1 Workbook	HCMO-BUY-012 to HCMO-BUY-018	Party C requests confidential treatment of certain information provided in the HCMO-1 Workbook. This information has not been made publicly available in any other forum. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in the party's operating model. The Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a "material change transaction". As such, Party C is requesting further confidential treatment of these materials.	ORS 192.345(23); ORS 415.501(13)(c)	Partially
5	Party D - HCMO-1 Workbook	HCMO-SELL-0034 to HCMO-SELL-0042	Party D requests confidential treatment of certain information provided in the HCMO-1 Workbook. This information has not been made publicly available in any other forum. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in the party's operating model. The Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a "material change transaction". As such, Party D is requesting further confidential treatment of these materials.	ORS 192.345(23); ORS 415.501(13)(c)	Partially

6	Appendix 7b - CVR Acquisition Diligence Reports	HCMO-BUY-ATT-001 to HCMO-BUY-ATT-062	The parties request confidential treatment of certain information provided in the diligence reports. This information has not been made publicly available in any other forum. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in the parties' operating model. The Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a "material change transaction". As such, the parties are requesting further confidential treatment of these materials.	ORS 192.345(23); ORS 415.501(13)(c)	Fully
7	Appendix 9(a)(1)	HCMO-SELL-ATT-0001 to HCMO-SELL-ATT-1027	The parties request confidential treatment of their respective Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"), filings and related materials submitted in connection with the Transaction. These materials contain highly sensitive, nonpublic business information, including strategic planning materials, competitive analyses, financial projections, transaction-related assessments, market evaluations, customer and supplier information, and other proprietary commercial information. Such information is treated as confidential internally, with access limited to legal, finance, corporate development, and senior management personnel, and is maintained in secure systems subject to confidentiality protocols. To the extent disclosed to third parties, including regulatory authorities and professional advisors, such information is provided pursuant to statutory protections, confidentiality obligations, or other applicable restrictions on disclosure. Public disclosure	ORS 192.345(23); ORS 415.501(13)(c)	Fully
8	Appendix 9a(2)	HCMO-BUY-ATT-063 to HCMO-BUY-ATT-1227	The parties request confidential treatment of their respective Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"), filings and related materials submitted in connection with the Transaction. These materials contain highly sensitive, nonpublic business information, including strategic planning materials, competitive analyses, financial projections, transaction-related assessments, market evaluations, customer and supplier information, and other proprietary commercial information. Such information is treated as confidential internally, with access limited to legal, finance, corporate development, and senior management personnel, and is maintained in secure systems subject to confidentiality protocols. To the extent disclosed to third parties, including regulatory authorities and professional advisors, such information is	ORS 192.345(2); ORS 415.501(13)(c); 15 U.S.C. § 18a(h);ORS 415.501(13)(c)	Fully
9	Appendix 10(c)	HCMO-BUY-ATT-1228 to HCMO-BUY-ATT-1230; HCMO-BUY-ATT-1228a to HCMO-BUY-ATT-1230a	The parties request confidential treatment of their pre- and post-closing organizational chart. As nonpublic entities, this information has not been made publicly available in any other forum. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in the companies' operating model. The Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a "material change transaction." As such, the parties are requesting further confidential treatment of their pre- and post-closing organizational charts, unless the parties provide written consent to publication.	ORS 192.345(2)); ORS 415.501(13)(c)	Partially
10	Appendix 10e	HCMO-SELL-ATT-1028 to HCMO-SELL-ATT-1057	The parties request confidential treatment of their Financial Statements. As nonpublic entities, this information has not been made publicly available in any other forum. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in the companies' operating model. The Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a "material change transaction." As such, the parties are requesting further confidential treatment of their Financial Statements, unless the parties provide written consent to publication.	ORS 192.345(2)); ORS 415.501(13)(c)	Fully

11	Securities Purchase Agreement	HCMO-BUY-ATT-1247 to HCMO-BUY-ATT-1502	The parties request confidential treatment of the Parties' Securities Purchase Agreement (the "SPA"). The information redacted in the SPA qualifies as a "trade secret" in that it is non public, competitively sensitive information that relates to the parties' business strategy and is known only by the executives who have certified this filing, their representatives, and the attorneys who have helped prepare the filing. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in the companies' operating models. The Parties request further confidential treatment of the SPA unless they provide their prior written consent.	ORS 192.345; ORS 415.501(13)(c)	Fully
12	Disclosure Schedules to SPA	HCMO-BUY-ATT-1503 to HCMO-BUY-ATT-1667	The parties request confidential treatment of the Parties' Disclosures Schedules to the SPA. The information redacted in the Disclosure Schedules qualifies as a "trade secret" under ORS 192.345 in that it is non public, competitively sensitive information that relates to the parties' business strategy and is known only by the executives who have certified this filing, their representatives, and the attorneys who have helped prepare the filing. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in the companies' operating models. The Parties request further confidential treatment of the Disclosure Schedules unless they provide their prior written consent.	ORS 192.345; ORS 415.501(13)(c)	Fully
13	Party B - Operating Agreement	HCMO-BUY-ATT-1668 to HCMO-BUY-ATT-1673	The parties request confidential treatment of the party's operating agreement. The information redacted in the operating agreement qualifies as a "trade secret" under ORS 192.345 in that it is non public, competitively sensitive information that relates to the party's business strategy and is known only by the executives who have certified this filing, their representatives, and the attorneys who have helped prepare the filing. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in the companies' operating models. The party requests further confidential treatment of the operating agreement unless they provide their prior written consent.	ORS 192.345; ORS 415.501(13)(c)	Fully
14	Party C - Operating Agreement	HCMO-BUY-ATT-1674 to HCMO-BUY-ATT-1681	The parties request confidential treatment of the party's operating agreement. The information redacted in the operating agreement qualifies as a "trade secret" under ORS 192.345 in that it is non public, competitively sensitive information that relates to the party's business strategy and is known only by the executives who have certified this filing, their representatives, and the attorneys who have helped prepare the filing. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in the companies' operating models. The party requests further confidential treatment of the operating agreement unless they provide their prior written consent.	ORS 192.345; ORS 415.501(13)(c)	Fully
15	HSR Notification and Report Form	HCMO-BUY-ATT-1682 to HCMO-BUY-ATT-1692	The parties request confidential treatment of the Parties' HSR Notification and Report Form (the "Form"). The information redacted in the Form qualifies as a "trade secret" under ORS 192.345 in that it is non public, competitively sensitive information that relates to the parties' business strategy and is known only by the executives who have certified this filing, their representatives, and the attorneys who have helped prepare the filing. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in the companies' operating models. The Parties request further confidential treatment of the Form unless they provide their prior written consent.	ORS 192.345; ORS 415.501(13)(c)	Fully

16 Responses to Incomplete Filing Notice	HCMO-SELL-ATT-1146 to HCMO-SELL-ATT-1147	The parties request confidential treatment of certain information provided in the Responses to Incomplete Filing Notice. This information has not been made publicly available in any other forum. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in the parties' operating model. and includes contact information for individuals. The Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a "material change transaction". As such, the parties are requesting further confidential treatment of these materials.	ORS 192.345(23); ORS 415.501(13)(c)	Partially